Anthony M. Del Rio

Hospitals & Healthcare Providers

• GTCR in its investment in Caravel Autism Health, a provider of applied behavior analysis therapy for children on the autism spectrum
• Boston Medical Center, one of the oldest and most renowned nonprofit hospital systems in the U.S. (BMC), in its successful acquisition of two Boston-area safety net hospitals, Good Samaritan and St. Elizabeth’s, from bankrupt Steward Healthcare System LLC. The transaction was approved by the U.S. Bankruptcy Court for the Southern District of Texas and closed on October 1, 2024
• Ascension, one of the largest private healthcare systems in the United States, in multiple strategic hospital transactions
• Buyer in acquisition of a controlling interest in $1.2 billion portfolio of net-leased hospitals located in Utah and $770 million financing
• General Catalyst and Health Assurance Transformation, LLC (HATCo) on the proposed combination of Summa Health with HATCo
• TPG Growth, LLC in its partnership with Novant Health to expand MedQuest
• Oak Street Health (NYSE: OSH) in its $10.6 billion sale to CVS Health (NYSE: CVS)
• TPG's The Rise Fund in its investment in Banyan Treatment Centers, a provider of substance use disorder and mental health services

Healthcare Technology

• GTCR, alongside Recognize, in the pending $632.4 million acquisition of TRANZACT from WTW (NASDAQ: WTW)
• Waud Capital Partners in its acquisition of Fusion Healthcare Staffing, a provider of locum tenens staffing services to hospitals and healthcare providers 
• Bain Capital-backed QuVa Pharma in its acquisition of LogicStream
• TPG’s The Rise Fund in its over $200 million investment in Foodsmart, a provider of telenutrition services and a food benefits management platform
• KKR in its investment Cotiviti
• Bain Capital-backed LeanTaaS in its acquisition of Hospital IQ, a provider of intelligent automation solutions for hospitals
• Madison Dearborn Partners and Thoma Bravo in their $1.4 billion sale of Syntellis Performance Solutions to Roper Technologies (NASDAQ: ROP)
• Bain Capital Insurance in its investment in Aptia, a provider of employee benefits and pensions administration service
• EW Healthcare Partners in its acquisition of Enercon Technologies, a provider of electronic product development and manufacturing services
• Bain Capital-backed LeanTaaS in its acquisition of Hospital IQ, a provider of intelligent automation solutions for hospitals
• Madison Dearborn Partners-backed Kaufman, Hall & Associates in its acquisition of Claro Healthcare, a healthcare consulting firm
• Zelis in its acquisitions of PaySpan and Payer Compass

Life Sciences

• Vyaire Medical in the sale of the Vyaire Respiratory Diagnostics (RDx) business unit, a manufacturer of respiratory diagnostic products, to Trudell Medical Limited
• Waud Capital Partners-backed PharmAlliance in its acquisition of Biobridges, a drug development consulting business, from Soliant Health
• RLS Radiopharmacies, a radiopharmacy network, in its pending $230 million sale to Telix Pharmaceuticals (ASX: TLX)
• Altaris in its pending acquisition of Minaris Regenerative Medicine, a provider of autologous and allogeneic manufacturing services for pharmaceutical and biotech customers, from Resonac
• Eli Lilly and Company (NYSE: LLY) in its $1.4 billion acquisition of POINT Biopharma (NASDAQ: PNT), a radiopharmaceutical company
• TJC in its sale of Worldwide Clinical Trials to Kohlberg & Company
• Eli Lilly in its divestiture of BAQSIMI to Amphastar Pharmaceuticals for up to $1.075 billion
• Water Street Healthcare Partners LLC in its acquisition of Avantik
• Waters Corporation in its $1.36 billion acquisition of Wyatt Technology

Restructuring

• Invitae Corporation and certain of its affiliates in their prearranged Chapter 11 cases in the U.S. Bankruptcy Court for the District of New Jersey. Invitae is headquartered in San Francisco, California and is a leader in the genetic testing field. Prior to commencing Chapter 11, Invitae secured support to implement a go-forward sale process by signing a transaction support agreement with a significant majority of its secured noteholders. Invitae is a publicly traded company and listed approximately $1.5 billion in funded debt obligations as of the petition date
• Genesis Care Pty Ltd and its affiliates in their Chapter 11 cases. GenesisCare is a leading cancer care provider, offering personalized and accessible treatment across a network of highly-skilled healthcare professionals to patients globally. GenesisCare is one of the world’s largest integrated oncology organizations and the world’s largest provider of radiotherapy, operating more than 400 cancer centers in the U.S., Australia, Spain and the UK which treat more than 450,000 patients annually. As of its Chapter 11 filing, GenesisCare’s funded debt totaled approximately $1.7 billion, including approximately $1.55 billion in secured term loan indebtedness. GenesisCare commenced its Chapter 11 cases to obtain access to debtor-in-possession financing, to conduct a marketing and sale process for its U.S. assets, and to restructure its financial obligations
• Envision Healthcare Corp. and 216 of its affiliates in the commencement of pre-arranged Chapter 11 cases. Envision is a leading national medical group that employs or partners with more than 21,000 clinicians and provides care to patients across the U.S., with nearly 30 million patient visits each year. The two restructuring support agreements contemplate a collective deleveraging of approximately $7.4 billion of secured and unsecured debt and the separation of Envision’s physician services and ambulatory surgical center businesses
• Pipeline Health System, LLC and its affiliates during their Chapter 11 cases. Pipeline Health operates seven “safety net” hospitals, three health clinics and three medical group centers across California, Texas and Illinois, including Weiss Memorial Hospital and West Suburban Medical Center in Chicago
• Carestream Health, Inc. and its debtor affiliates during their prepackaged Chapter 11 cases. Carestream, a Rochester, New York based global provider of medical imaging systems and non-destructive testing products had more than $1.3 billion of prepetition funded debt obligations

President, Rush Health